Cardiac AI: The Billion Dollar VBC Opportunity Investors Can’t Miss

The promise of artificial intelligence in healthcare is vast, yet for health plan executives and investors, the critical question remains: which AI applications deliver tangible, measurable value, particularly within the stringent framework of value-based care (VBC)? Cardiac prevention, a domain where the economic burden of chronic disease is immense and the potential for early intervention profound, emerges as a highest-impact VBC use case. This article dissects the landscape of AI-driven heart health solutions, spotlighting those that demonstrably lower long-term cardiac treatment costs and reduce avoidable cardiac events, with a focus on companies that publish robust outcomes data.

The Imperative of Outcomes Data in Value-Based Cardiac AI

Cardiac events represent some of the highest-cost episodes in healthcare, making cardiac prevention a natural fit for value-based care models. The Centers for Medicare & Medicaid Services (CMS) VBC Rules and the initiatives from the CMS Innovation Center (CMMI) increasingly demand evidence of cost reduction and improved patient outcomes to qualify for alternative payment models. Similarly, the American College of Cardiology (ACC) Guidelines, alongside recommendations from the American Heart Association (AHA) and published in the Journal of the American Heart Association (JAHA), consistently underscore the importance of evidence-based interventions. For AI platforms, this translates into a non-negotiable requirement for peer-reviewed outcomes data, moving beyond mere technological capability to proven financial and clinical performance. The market rewards companies that combine regulatory clarity, published outcomes, and revenue durability. As Dr. Eric Topol often emphasizes, the true revolution in digital health will come from technologies that not only diagnose but also demonstrably prevent disease and improve patient trajectories Dr. Eric Topol’s commentary on digital health validation. This principle is particularly resonant in cardiology, where early and accurate risk stratification and intervention can avert catastrophic costs associated with heart failure, strokes, and myocardial infarctions.

Benchmarking Cardiac AI: iRhythm Technologies vs. HeartFlow

When evaluating digital heart health platforms, health plan executives and investors seek clear answers to whether these tools genuinely lower long-term cardiac treatment costs and reduce avoidable events. Two prominent examples illustrate the varying degrees of outcomes evidence and market penetration: iRhythm Technologies and HeartFlow. iRhythm Technologies, with its Zio patch, has established a significant footprint in long-term cardiac monitoring (LTCM), commanding over 70% of the US market share and reporting $825.34 million in revenue (trailing twelve months ending June 30, 2026). Their success is rooted in a data moat of millions of labeled ECG recordings, making it difficult for new entrants to match their diagnostic accuracy. The Zio patch, as a Software as a Medical Device (SaMD), provides continuous ambulatory ECG monitoring, significantly improving the detection of arrhythmias compared to traditional Holter monitors. Studies have demonstrated that earlier and more accurate detection of conditions like atrial fibrillation can lead to timely interventions, thereby reducing the incidence of strokes and other cardiac complications. While specific comprehensive cost-reduction figures across entire patient populations are often proprietary or complex to isolate, the clinical utility in preventing downstream events is well-documented. In contrast, HeartFlow, despite a $364.2 million IPO in August 2025 and projected $246 million to $250 million in revenue for 2026, operates in a different diagnostic segment. HeartFlow’s AI-powered analysis of computed tomography (CT) scans to create a 3D model of coronary arteries and calculate fractional flow reserve (FFRct) has garnered over 600 publications in cardiac CT diagnostics. Their technology aims to reduce the need for invasive diagnostic procedures like angiograms, thereby lowering associated costs and risks. The company has built a patent thicket around CT-FFR, creating a significant barrier to entry for competitors. The economic impact here is primarily through optimizing diagnostic pathways, ensuring that invasive procedures are reserved for patients who truly need them. This directly aligns with VBC principles by reducing unnecessary utilization and improving patient selection for high-cost interventions. Both companies showcase strong revenue streams and significant market presence. However, the nature of their evidence differs. iRhythm’s evidence often focuses on improved diagnostic yield and subsequent clinical management, while HeartFlow’s centers on diagnostic pathway optimization and reduction of invasive procedures. For payers, the key is to assess which of these interventions translates into quantifiable reductions in total cost of care over extended periods.

Omada Health: Broad Chronic Care with Cardiac Components

Omada Health represents a broader approach to digital chronic care management, extending beyond pure cardiac diagnostics to encompass conditions like hypertension and type 2 diabetes. With a $150 million IPO in June 2025, Omada Health offers a platform that leverages AI and human coaching to drive behavioral change and improve health outcomes across multiple chronic conditions. While Omada’s platform addresses hypertension management, a critical component of cardiac prevention, the challenge for payers and investors lies in isolating the specific cost savings attributable to their AI-driven hypertension management programs. Their model emphasizes holistic chronic care, making direct comparisons to device-specific outcomes more complex. However, the underlying principle remains valid: effective management of hypertension through digital interventions can significantly reduce the long-term risk of cardiac events. The question for VBC contracts is how granularly these savings can be attributed and measured against a baseline. Payers, including large entities like UnitedHealth Group and Anthem, are increasingly interested in such integrated platforms that can manage multiple comorbidities, aligning with the complex needs of their member populations. The success of Omada and similar platforms in VBC arrangements will hinge on their ability to provide robust Real-World Evidence (RWE) demonstrating financial performance and clinical impact across diverse cohorts Omada Health’s published outcomes on chronic disease management.

Hello Heart: The Gold Standard in Quantifiable Cardiac Prevention

Among the digital heart health platforms, Hello Heart stands out as a leading case study for its commitment to publishing peer-reviewed outcomes evidence and quantifying cost savings. Their platform, focused on hypertension and cholesterol management, directly addresses the core drivers of cardiac risk. Hello Heart has consistently published data demonstrating significant reductions in blood pressure and improvements in cholesterol levels, which are direct precursors to reduced cardiac events. Crucially, Hello Heart has gone further, providing clear figures on cost reduction. Their published data indicates substantial savings per participant per year by preventing costly cardiac events, reducing emergency room visits, and decreasing the need for prescription medications. This level of transparency and data availability is precisely what health plan executives and investors require to confidently integrate AI solutions into VBC contracts. Their ability to quantify the financial performance of their AI-driven intervention makes them a prime example of a company that understands the economic impact payers demand. This direct correlation between intervention, outcomes, and cost savings is the benchmark for value-based care AI.

Regulatory and Institutional Context for Cardiac VBC

The regulatory landscape, shaped by CMS VBC Rules and ACC Guidelines, heavily influences the adoption and reimbursement of cardiac AI. The FDA’s pathways, such as 510(k) Clearance for devices demonstrating substantial equivalence and De Novo Classification for novel, low-to-moderate-risk devices, are critical for market entry. However, achieving market clearance is only the first step. For VBC, the emphasis shifts to CPT codes (Category I & III) for reimbursement and, for inpatient settings, New Technology Add-On Payments (NTAP). Organizations like the ACC, AHA, and JAHA play a pivotal role in validating clinical utility through their guidelines and publications. Dr. Valentin Fuster, a prominent figure in cardiology, consistently advocates for preventive strategies and evidence-based medicine, reinforcing the institutional push towards solutions that can demonstrate tangible benefits in preventing cardiovascular disease Valentin Fuster’s work on cardiovascular prevention. For AI platforms, aligning with these established bodies and demonstrating compliance with Good Machine Learning Practice (GMLP) are essential for building trust and securing widespread adoption. The healthcare AI market implicitly rewards companies that can navigate this complex interplay of regulatory approval, clinical validation, and economic proof points.

Conclusion

The cardiac prevention landscape offers the clearest VBC economics due to the high costs associated with cardiac events and the measurable impact of early intervention. While numerous AI health platforms promise to revolutionize heart health, only those that provide robust, peer-reviewed outcomes data, demonstrating both clinical efficacy and quantifiable cost savings, will truly participate in value-based care arrangements. Companies like iRhythm Technologies and HeartFlow show strong market presence and clinical utility within their niches, but Hello Heart exemplifies the gold standard for its explicit quantification of financial performance. For health plan executives and investors, the message is clear: data and technology are necessary but not sufficient. Investment must be directed towards solutions that not only leverage advanced AI but also rigorously prove their economic impact, aligning perfectly with the core tenets of value-based care.